Yuzhuo Wang, Xiaoxi Ma, Haoze Cen, Jie Wang, Jie Wu, Ding Ding, Yiqin Xiao, Qianhua Zhao
{"title":"在视网膜神经纤维层变薄与12年痴呆之间的关系中,APOE ε4非依赖性通路占主导地位","authors":"Yuzhuo Wang, Xiaoxi Ma, Haoze Cen, Jie Wang, Jie Wu, Ding Ding, Yiqin Xiao, Qianhua Zhao","doi":"10.1002/trc2.70104","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> INTRODUCTION</h3>\n \n <p>Emerging evidence links retinal nerve fiber layer (RNFL) thinning to cognitive impairment, while the apolipoprotein E (<i>APOE</i>) ε4 allele, the key genetic dementia risk factor, is also found to be associated with RNFL thickness. This study investigated the longitudinal association between RNFL thinning and 12-year dementia risk, evaluated the role of <i>APOE</i> ε4 in this relationship, and clarified the independent value of retinal imaging as a predictive biomarker for dementia.</p>\n </section>\n \n <section>\n \n <h3> METHODS</h3>\n \n <p>This study included 35,433 participants from the UK Biobank. Generalized linear models and Jonckheere-Terpstra tests assessed the association between <i>APOE</i> ε4 allele dosage and macular RNFL (mRNFL) thickness. Cox models evaluated the association between mRNFL thickness and incident dementia. To address potential confounding by <i>APOE</i> ε4, inverse probability weighting was applied. Mediation analysis quantified the contribution of <i>APOE</i> pathways to the mRNFL-dementia association.</p>\n </section>\n \n <section>\n \n <h3> RESULTS</h3>\n \n <p>Among 35,433 participants, 392 (1.11%) developed dementia over a median follow-up of 12.49 years (interquartile range: 12.39 to 12.64). <i>APOE</i> ε4 carriers exhibited a dose-dependent reduction in mRNFL thickness (β = −0.14, 95% confidence interval [CI]: −0.23 to −0.05, <i>p</i> = 0.002). After adjusting for age, sex, vascular risk factors, and <i>APOE</i> ε4 carrier status, the lowest mRNFL quintile group had a 64% higher dementia risk compared to the highest quintile (hazard ratio [HR] = 1.64, 95% CI: 1.17 to 2.30, <i>p</i> = 0.004). Each 5-µm reduction in mRNFL thickness corresponded to a 15% increased risk (HR = 1.15, 95% CI: 1.02 to 1.30, <i>p</i> = 0.02), which remained significant after inverse probability weighting. Mediation analysis revealed that <i>APOE</i> pathways accounted for 7.6% (95% CI: 2.6% to 28.6%, <i>p</i> = 0.01) of the mRNFL-dementia association.</p>\n </section>\n \n <section>\n \n <h3> DISCUSSION</h3>\n \n <p>Our findings resolve a controversy by showing that while <i>APOE</i> ε4 accelerates mRNFL degeneration, retinal imaging captures dementia-related neuropathology through pathways distinct from direct <i>APOE</i> effects, solidifying its potential as an etiologically informative biomarker.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>The association between <i>APOE</i> ε4 carriers and thinner RNFL was solidified by the J-T test and multiple linear regression, indicating genetic influence on retinal structure.</li>\n \n <li>After inverse probability weighting adjustment, each 5-µm reduction in baseline RNFL thickness increased dementia risk by 15%, highlighting its long-term predictive value.</li>\n \n <li>Only 7.6% of the effect of RNFL thickness on dementia risk was attributable to <i>APOE</i> status, underscoring the value of RNFL as a standalone, non-invasive biomarker in the assessment of long-term dementia risk.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":53225,"journal":{"name":"Alzheimer''s and Dementia: Translational Research and Clinical Interventions","volume":"11 2","pages":""},"PeriodicalIF":4.9000,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/trc2.70104","citationCount":"0","resultStr":"{\"title\":\"APOE ε4-independent pathways predominate in the association between retinal nerve fiber layer thinning and 12-year incident dementia\",\"authors\":\"Yuzhuo Wang, Xiaoxi Ma, Haoze Cen, Jie Wang, Jie Wu, Ding Ding, Yiqin Xiao, Qianhua Zhao\",\"doi\":\"10.1002/trc2.70104\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> INTRODUCTION</h3>\\n \\n <p>Emerging evidence links retinal nerve fiber layer (RNFL) thinning to cognitive impairment, while the apolipoprotein E (<i>APOE</i>) ε4 allele, the key genetic dementia risk factor, is also found to be associated with RNFL thickness. This study investigated the longitudinal association between RNFL thinning and 12-year dementia risk, evaluated the role of <i>APOE</i> ε4 in this relationship, and clarified the independent value of retinal imaging as a predictive biomarker for dementia.</p>\\n </section>\\n \\n <section>\\n \\n <h3> METHODS</h3>\\n \\n <p>This study included 35,433 participants from the UK Biobank. Generalized linear models and Jonckheere-Terpstra tests assessed the association between <i>APOE</i> ε4 allele dosage and macular RNFL (mRNFL) thickness. Cox models evaluated the association between mRNFL thickness and incident dementia. To address potential confounding by <i>APOE</i> ε4, inverse probability weighting was applied. Mediation analysis quantified the contribution of <i>APOE</i> pathways to the mRNFL-dementia association.</p>\\n </section>\\n \\n <section>\\n \\n <h3> RESULTS</h3>\\n \\n <p>Among 35,433 participants, 392 (1.11%) developed dementia over a median follow-up of 12.49 years (interquartile range: 12.39 to 12.64). <i>APOE</i> ε4 carriers exhibited a dose-dependent reduction in mRNFL thickness (β = −0.14, 95% confidence interval [CI]: −0.23 to −0.05, <i>p</i> = 0.002). After adjusting for age, sex, vascular risk factors, and <i>APOE</i> ε4 carrier status, the lowest mRNFL quintile group had a 64% higher dementia risk compared to the highest quintile (hazard ratio [HR] = 1.64, 95% CI: 1.17 to 2.30, <i>p</i> = 0.004). Each 5-µm reduction in mRNFL thickness corresponded to a 15% increased risk (HR = 1.15, 95% CI: 1.02 to 1.30, <i>p</i> = 0.02), which remained significant after inverse probability weighting. Mediation analysis revealed that <i>APOE</i> pathways accounted for 7.6% (95% CI: 2.6% to 28.6%, <i>p</i> = 0.01) of the mRNFL-dementia association.</p>\\n </section>\\n \\n <section>\\n \\n <h3> DISCUSSION</h3>\\n \\n <p>Our findings resolve a controversy by showing that while <i>APOE</i> ε4 accelerates mRNFL degeneration, retinal imaging captures dementia-related neuropathology through pathways distinct from direct <i>APOE</i> effects, solidifying its potential as an etiologically informative biomarker.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Highlights</h3>\\n \\n <div>\\n <ul>\\n \\n <li>The association between <i>APOE</i> ε4 carriers and thinner RNFL was solidified by the J-T test and multiple linear regression, indicating genetic influence on retinal structure.</li>\\n \\n <li>After inverse probability weighting adjustment, each 5-µm reduction in baseline RNFL thickness increased dementia risk by 15%, highlighting its long-term predictive value.</li>\\n \\n <li>Only 7.6% of the effect of RNFL thickness on dementia risk was attributable to <i>APOE</i> status, underscoring the value of RNFL as a standalone, non-invasive biomarker in the assessment of long-term dementia risk.</li>\\n </ul>\\n </div>\\n </section>\\n </div>\",\"PeriodicalId\":53225,\"journal\":{\"name\":\"Alzheimer''s and Dementia: Translational Research and Clinical Interventions\",\"volume\":\"11 2\",\"pages\":\"\"},\"PeriodicalIF\":4.9000,\"publicationDate\":\"2025-05-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/trc2.70104\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alzheimer''s and Dementia: Translational Research and Clinical Interventions\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/trc2.70104\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer''s and Dementia: Translational Research and Clinical Interventions","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/trc2.70104","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
APOE ε4-independent pathways predominate in the association between retinal nerve fiber layer thinning and 12-year incident dementia
INTRODUCTION
Emerging evidence links retinal nerve fiber layer (RNFL) thinning to cognitive impairment, while the apolipoprotein E (APOE) ε4 allele, the key genetic dementia risk factor, is also found to be associated with RNFL thickness. This study investigated the longitudinal association between RNFL thinning and 12-year dementia risk, evaluated the role of APOE ε4 in this relationship, and clarified the independent value of retinal imaging as a predictive biomarker for dementia.
METHODS
This study included 35,433 participants from the UK Biobank. Generalized linear models and Jonckheere-Terpstra tests assessed the association between APOE ε4 allele dosage and macular RNFL (mRNFL) thickness. Cox models evaluated the association between mRNFL thickness and incident dementia. To address potential confounding by APOE ε4, inverse probability weighting was applied. Mediation analysis quantified the contribution of APOE pathways to the mRNFL-dementia association.
RESULTS
Among 35,433 participants, 392 (1.11%) developed dementia over a median follow-up of 12.49 years (interquartile range: 12.39 to 12.64). APOE ε4 carriers exhibited a dose-dependent reduction in mRNFL thickness (β = −0.14, 95% confidence interval [CI]: −0.23 to −0.05, p = 0.002). After adjusting for age, sex, vascular risk factors, and APOE ε4 carrier status, the lowest mRNFL quintile group had a 64% higher dementia risk compared to the highest quintile (hazard ratio [HR] = 1.64, 95% CI: 1.17 to 2.30, p = 0.004). Each 5-µm reduction in mRNFL thickness corresponded to a 15% increased risk (HR = 1.15, 95% CI: 1.02 to 1.30, p = 0.02), which remained significant after inverse probability weighting. Mediation analysis revealed that APOE pathways accounted for 7.6% (95% CI: 2.6% to 28.6%, p = 0.01) of the mRNFL-dementia association.
DISCUSSION
Our findings resolve a controversy by showing that while APOE ε4 accelerates mRNFL degeneration, retinal imaging captures dementia-related neuropathology through pathways distinct from direct APOE effects, solidifying its potential as an etiologically informative biomarker.
Highlights
The association between APOE ε4 carriers and thinner RNFL was solidified by the J-T test and multiple linear regression, indicating genetic influence on retinal structure.
After inverse probability weighting adjustment, each 5-µm reduction in baseline RNFL thickness increased dementia risk by 15%, highlighting its long-term predictive value.
Only 7.6% of the effect of RNFL thickness on dementia risk was attributable to APOE status, underscoring the value of RNFL as a standalone, non-invasive biomarker in the assessment of long-term dementia risk.
期刊介绍:
Alzheimer''s & Dementia: Translational Research & Clinical Interventions (TRCI) is a peer-reviewed, open access,journal from the Alzheimer''s Association®. The journal seeks to bridge the full scope of explorations between basic research on drug discovery and clinical studies, validating putative therapies for aging-related chronic brain conditions that affect cognition, motor functions, and other behavioral or clinical symptoms associated with all forms dementia and Alzheimer''s disease. The journal will publish findings from diverse domains of research and disciplines to accelerate the conversion of abstract facts into practical knowledge: specifically, to translate what is learned at the bench into bedside applications. The journal seeks to publish articles that go beyond a singular emphasis on either basic drug discovery research or clinical research. Rather, an important theme of articles will be the linkages between and among the various discrete steps in the complex continuum of therapy development. For rapid communication among a multidisciplinary research audience involving the range of therapeutic interventions, TRCI will consider only original contributions that include feature length research articles, systematic reviews, meta-analyses, brief reports, narrative reviews, commentaries, letters, perspectives, and research news that would advance wide range of interventions to ameliorate symptoms or alter the progression of chronic neurocognitive disorders such as dementia and Alzheimer''s disease. The journal will publish on topics related to medicine, geriatrics, neuroscience, neurophysiology, neurology, psychiatry, clinical psychology, bioinformatics, pharmaco-genetics, regulatory issues, health economics, pharmacoeconomics, and public health policy as these apply to preclinical and clinical research on therapeutics.